The global tumor ablation market is witnessing strong expansion as healthcare providers increasingly adopt minimally invasive approaches for treating localized tumors. Tumor ablation destroys cancerous tissue without requiring conventional surgical removal and can be particularly useful for patients with a limited number of small tumors or for those who may not be suitable candidates for surgery. Rising cancer prevalence, an aging population, advances in image-guided interventions, and growing preference for procedures associated with shorter recovery times are supporting the adoption of tumor ablation technologies worldwide. According to Grand View Research, the market is expected to maintain strong momentum through 2033 as hospitals and specialty centers increasingly integrate advanced ablation systems into interventional oncology practices. 

Market Growth and Key Trends

According to Grand View Research, the global tumor ablation market was valued at USD 2.1 billion in 2025 and is estimated to reach USD 2.4 billion in 2026. The market is projected to reach USD 6.1 billion by 2033, expanding at a CAGR of 14.1% from 2026 to 2033. 

The growth of the industry is closely linked to the increasing incidence of cancer and the growing demand for treatment approaches that minimize trauma and recovery time. Ablation can be performed through different approaches, including percutaneous, laparoscopic, and surgical techniques, depending on tumor location, size, and clinical requirements.

Technological innovation is also improving the precision and effectiveness of tumor ablation. Developments in image guidance, intraprocedural imaging, 3D visualization, fusion imaging, and navigation software are helping clinicians plan procedures and assess the ablation zone more accurately. These technologies are particularly valuable when tumors are located in anatomically challenging areas such as the liver, kidneys, and lungs. 

Download a free sample copy of the Tumor Ablation Market report to understand detailed coverage and inclusions in the final report

Technology Landscape

Radiofrequency ablation (RFA) held the leading position among technologies, accounting for a 32.9% revenue share in 2025. RFA uses high-frequency electrical energy to generate heat and destroy targeted tumor tissue. Its minimally invasive nature and established clinical use have supported adoption across different oncology applications. 

RFA is particularly relevant for localized tumors and selected patients for whom conventional surgery may not be appropriate. The technique can be performed with image guidance, allowing clinicians to position the ablation probe accurately within the target tissue. Its outpatient potential and reduced recovery burden compared with some conventional interventions further contribute to its attractiveness.

Meanwhile, microwave ablation is expected to be the fastest-growing technology segment, registering a 14.9% CAGR over the forecast period. Microwave ablation uses electromagnetic energy to generate heat within tumor tissue and offers advantages in tumor destruction effectiveness. Increasing adoption of microwave-based systems is expected to strengthen the competitive dynamics of the technology segment. 

Other technologies covered by Grand View Research include cryoablation, irreversible electroporation ablation, high-intensity focused ultrasound (HIFU), and other ablation technologies. These approaches provide physicians with different mechanisms for destroying tumors and expanding treatment possibilities across various cancer types. 

Treatment Approaches Expand Clinical Applications

The percutaneous ablation segment held a leading market share in 2025. Percutaneous procedures can be performed through the skin under imaging guidance, allowing clinicians to target tumors while minimizing surgical intervention. The approach is particularly attractive because it can reduce hospital stays and support faster recovery in appropriate patients. 

Laparoscopic ablation is another important treatment approach and is expected to be the fastest-growing treatment segment. It provides clinicians with an alternative route for treating tumors while limiting the extent of conventional open surgery.

The increasing focus on minimally invasive oncology is a major factor supporting these approaches. Compared with invasive procedures, minimally invasive techniques can reduce trauma and recovery requirements, although patient suitability depends on tumor characteristics and clinical assessment. 

Liver Cancer Leads Application Demand

Among applications, liver cancer held a leading market share in 2025. Tumor ablation has become an important treatment option for selected liver tumors, particularly when surgery is unsuitable or when preserving surrounding tissue is important. The ability to precisely target localized lesions has contributed to the adoption of ablation systems in liver cancer treatment. 

Kidney, breast, prostate, and other cancers also represent important application areas. As imaging capabilities and ablation technologies improve, physicians are gaining greater ability to target tumors located in different organs while attempting to preserve healthy surrounding tissue.

North America Maintains Regional Leadership

North America dominated the tumor ablation market with a 42.4% revenue share in 2025. The region benefits from advanced healthcare infrastructure, high healthcare expenditure, reimbursement availability, increasing cancer incidence, and strong adoption of innovative medical technologies. The U.S. accounted for the largest country-level revenue share in 2025. 

Asia Pacific is expected to be the fastest-growing regional market during the forecast period. Increasing cancer incidence, improving healthcare infrastructure, growing awareness of minimally invasive treatments, and expansion of healthcare services in countries such as China, Japan, and India are creating substantial opportunities. 

India represents an important emerging opportunity. Grand View Research notes that the country faces a substantial cancer burden, while government screening and diagnostic initiatives and the benefits associated with tumor ablation are supporting future demand. 

Looking for more specific insights? Customize this report to suite your business needs

Innovation and Competitive Landscape

The tumor ablation industry is moderately concentrated, with established medical device companies investing in new energy-delivery platforms, image-guided systems, and specialized applications. 

Key companies profiled by Grand View Research include:

• Medtronic plc

• Boston Scientific Corporation

• Johnson & Johnson Service Inc. (Ethicon, Inc.)

• AngioDynamics

• Bioventus Inc. (Misonix Inc.)

• EDAP TMS

• Chongqing Haifu Medical Technology Co., Ltd

• Mermaid Medical

• HealthTronics, Inc.

• H.S. Hospital Service S.p.A.

Strategic partnerships, regulatory approvals, product launches, and geographic expansion are shaping competition. In March 2024, Medtronic received U.S. FDA clearance for its OsteoCool 2.0 bone tumor ablation system. Such developments demonstrate the industry's focus on expanding ablation applications beyond traditional tumor sites.